← Back to Search

Telehealth Assessment for Alzheimer's Disease (VITAL-NP Trial)

N/A
Recruiting
Led By Brianne Bettcher, PhD
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to two years
Awards & highlights

VITAL-NP Trial Summary

This trial is testing whether a home-based assessment for Alzheimer's Disease is as effective as an in-person assessment.

Who is the study for?
This trial is for individuals aged 60-90 who are being evaluated for possible Alzheimer's Disease, ranging from mild cognitive impairment to mild dementia. They must be suspected of having typical or atypical AD by a neurologist. Those with moderate/severe dementia, active delirium, legal blindness/deafness, brain tumors, non-AD neurological diagnoses like MS or FTD, substance abuse or major psychiatric disorders cannot participate.Check my eligibility
What is being tested?
The VITAL-NP study aims to test the effectiveness of home-based TeleNP (telehealth neuropsychology) assessments compared to traditional face-to-face evaluations in diagnosing Alzheimer's Disease. It will determine if TeleNP can reliably distinguish between typical and atypical forms of AD as well as an in-person assessment.See study design
What are the potential side effects?
Since this trial involves cognitive assessments rather than medication or invasive procedures, there are no direct physical side effects expected from participating in either the TeleNP evaluation or the face-to-face evaluation.

VITAL-NP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to two years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to two years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Acceptability and Feasibility of Intervention Measures as Measured by 19-item UTAUT questionnaire adapted to TeleNP
Acceptability and Feasibility of Intervention Measures as measured by 4-item Acceptability and Feasibility of Intervention Measures Scale
Equivalence of Cognitive Test Results Across Testing Modalities as measured by Neuropsychological Test Mean Scores
+5 more

VITAL-NP Trial Design

2Treatment groups
Experimental Treatment
Group I: TeleNP evaluation, Face-to-face evaluation (FF)Experimental Treatment2 Interventions
Group II: Face-to-face evaluation (FF), TeleNP evaluationExperimental Treatment2 Interventions

Find a Location

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,722 Previous Clinical Trials
2,113,422 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,653 Previous Clinical Trials
28,004,895 Total Patients Enrolled
Brianne Bettcher, PhDPrincipal InvestigatorUniversity of Colorado - Anschutz Medical Campus

Media Library

Face-to-face evaluation (FF) Clinical Trial Eligibility Overview. Trial Name: NCT05379023 — N/A
Alzheimer's Disease Research Study Groups: Face-to-face evaluation (FF), TeleNP evaluation, TeleNP evaluation, Face-to-face evaluation (FF)
Alzheimer's Disease Clinical Trial 2023: Face-to-face evaluation (FF) Highlights & Side Effects. Trial Name: NCT05379023 — N/A
Face-to-face evaluation (FF) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05379023 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals have been registered for this medical research?

"Affirmatively, the details hosted on clinicaltrials.gov indicate that this research endeavour is actively recruiting participants since its initial posting of June 27th 2022 and most recent update of September 2nd 2022. They are aiming to recruit 80 individuals from 1 site in particular."

Answered by AI

What criteria must volunteers meet to be eligible for this research?

"This clinical study is enrolling 80 participants, aged between 60 and 90 years old who have Alzheimer's disease. In addition to these conditions, potential subjects should meet the following criteria: they must be in their sixties up until nineties with a diagnosis of either common AD or aberrant AD according to their neurologist's judgement; additionally, there needs to be evidence that patient's condition ranges from Mild cognitive impairment (MCI) all the way through mild dementia."

Answered by AI

Does this research have any open enrollment spots for participants?

"Affirmative. According to clinicaltrials.gov, the medical study which made its debut on June 27th 2022 is currently recruiting patients. The trial requires 80 individuals from 1 location for it to be successful."

Answered by AI

Does this clinical trial include participants over seventy years of age?

"To be deemed eligible for this trial, prospective participants must fall between the ages of 60 and 90. Additionally, there are 23 studies available to those under 18 and a total of 538 trials open to individuals over 65."

Answered by AI
~29 spots leftby Mar 2025